To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Tirzepatide treatment was associated with improved insulin sensitivity and β-cell function regardless of weight loss among patients with obesity.

Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Scholar Rock ...

Treatment with tirzepatide led to significant weight loss in adults with obesity or overweight with weight-related comorbidities (excluding type 2 diabetes), according to results from the phase 3 ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

NEW ORLEANS — Nearly all participants with obesity without diabetes assigned tirzepatide experienced at least 5% weight loss over 72 weeks compared with placebo, with at least 20% weight loss in ...

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist ...

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

The US drugmaker Eli Lilly has bowed to demands from Donald Trump by raising the prices of its weight-loss jab for UK ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...